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Abstract OBJECTIVES: Fetal maturity does not seem to be directly connected with the phe-
nomenon of immune tolerance during pregnancy although the fetal maturation 
influences the process of initiation of the labor at term finishing the immune tol-
erance during pregnancy. CAP and RCAS1 are expressed by the trophoblast cells 
and afterwards by the placenta, these proteins are able to modulate the maternal 
immune response.   
MATERIALS AND METHODS: 160 patients were randomly selected to our study. The 
patients were divided into two groups using K score according to the newborn’s 
maturity: maturated and not fully maturated. Within the groups of matured and 
not fully matured newborns the subgroups were selected according to the type 
of the labor: spontaneous or induced. The oxytocinase plasma activity was estab-
lished in plasma samples obtained from pregnant women a few days before deliv-
ery. The placental RCAS1 relative amount was assessed by Western blot analysis.
RESULTS: The differences in oxytocinase plasma level with respect to the fetal 
maturity were identified in our study however no RCAS1 expression changes were 
found regarding the fetal maturation. We determined the alterations in RCAS1 
expression with respect to the occurrence of clinical symptoms of the spontane-
ous beginning of the labor in maturated and not-fully maturated groups of new-
borns.   
CONCLUSIONS: Oxytocinase seems to be a useful marker of normal fetal devel-
opment. The assessment of RCAS1 in placenta directly after delivery appears to 
indicate the level of maternal immune tolerance during the labor initiation. The 
level of the immune tolerance at the moment of the delivery drops independently 
of the fetal maturity.  
Introduction
The phenomenon of maternal immune toler-
ance during pregnancy to fetal antigens explains 
the possibility of fetal growth within maternal 
uterus. In 1950-ies Medwar suggested that the 
suppression of maternal lymphocytes might 
explain this process [23]. Fetal growth within 
maternal uterus is much more complex however 
the suppression of activated lymphocytes is one 
of its major elements [6,45]. The finishing of this 
process when the fetus reaches the maturity is 
the beginning of the labor [14,20]. The cytotoxic 
immune response grows gradually with the labor 
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progress [9,43]. The preterm labor which is the labor 
of immature fetus is similarly to labor at term char-
acterized by changes in maternal immune response 
activation, but the initiating mechanism is different. 
The existence of such a complex process as the maternal 
immune tolerance is determined by the unique mucosa 
associated lymphoid tissue within endometrium and 
the role of endometrial cells and trophoblast cells in the 
process of immune regulation. Both endometrium and 
endometrium associated lymphoid tissue are controlled 
by hormones according to menstrual cycle changes [10]. 
The recruitment of NK, NKT cells and macrophages to 
the decidua starts during the secretory cycle phase so 
they constitute almost 95% of all immune cells popula-
tion within decidua [13]. Mononuclear cells accumula-
tion is assisted by growing number of CD4+CD25high 
regulatory T cells within decidua, which present ability 
for immunsupression [11,36,37]. Mainly these cells 
determine the normal course of pregnancy from ovum 
implantation until the labor. The activity of immuno-
logical system is controlled not only by the decidual 
cells but also by trophoblast cells through the secretion 
of various factors eg. cytokins (IL-4, IL-10), hormones 
(HCG, ACTH), chemokins (CCL22) the expression of 
various proteins: Fas/FasL (death-inducing signaling 
complex/CD95/APO-1), indoleamine 2,3 dioxygen-
ase (IDO), killer inhibitory receptor family (KIR), 
receptor-binding cancer antigen expressed on SiSo 
cells (RCAS1), oxytocinase/cystine amino peptidase 
(CAP, EC 3.4.11.3), leukemia inhibitory factor (LIF) 
[11,12,16,18,25,30,31,35,49]. The decidua, trophoblast 
and immunological cells all create the phenomenon 
of maternal immune tolerance to fetal antigens. CAP 
and RCAS1 are expressed by the trophoblast cells and 
afterwards by the placenta (syncytiotrophoblast and 
cytotrophoblast), these proteins are able to modulate 
the maternal immune response [27,28]. 
Oxytocinase is responsible for the degradation of 
oxytocin and other active peptide hormones which 
are crucial for the normal development of pregnancy 
[14,17–19,21]. Oxytocinase expression grows gradually 
during the pregnancy until the labor, the changes in 
CAP plasma level can be observed in pregnant women 
as the result of CAP secretion to the maternal plasma. 
It was shown that the lack of CAP palsma level increase 
is concomitant to pregnancy loss, preeclampsia and 
preterm birth [18]. 
RCAS1 is a protein which was demonstrated  in 
various human cancer cells, responsible for tumor 
escape from host immunological surveillance however 
RCAS1 is not only the marker of cancer process, but 
its expression was also observed in physiological condi-
tions and the development of non-neoplastic tumors 
[1,27,28,32,40,41,49]. It was demonstrated in bone mar-
row, endometrium, decidua, placenta, Waldeyer’s ring, 
and immune mediated diseases [1,7,22,48,51]. RCAS1 
seems to be responsible for the regulation of the activity 
of cytotoxic cells. 
The aim of the present study was to evaluate the 
RCAS1 placental expression and CAP plasma level 
regarding the newborn maturity.  
Material and methods
Human subject
We recruited 950 women from the patients deliv-
ered at Gynecology and Infertility Department of 
the Jagiellonian University between March 2002 and 
March 2004. From this group of patients (950 women) 
160 patients were randomly selected to our study. 
The newborn maturity was evaluated directly after 
the delivery using K score, pointed by Klimek [20]. 
The patients were divided into two groups according 
to the newborns’ maturity: maturated and not fully 
maturated. The first group included 129 women from 
whom newborns were classified as fully maturated 
(more than 9 points in K score). The second group 
consisted of patients from whom newborns were clas-
sified as not fully maturated (more than 6 but less than 
9 points in K score) (Table 1). In both groups patients 
after vaginal labors (73%) and cesareans (27%) were 
included. Within the two main groups of matured 
and not fully matured newborns the subgroups were 
selected according to the type of the labor: spontaneous 
or induced. Within the spontaneous labor subgroup 
women with vaginal delivery of spontaneous onset and 
regular uterine contractions were included as well as 
women after cesareans performed during the first stage 
of labor with ripe cervix and regular uterine contrac-
tions. Within the induced labor subgroup women with 
vaginal delivery induced by oxytocin and cesareans 
performed with unripe cervix, without regular uterine 
contractions were included.
Patients with recurrent miscarriage, pervious 
cesarean section, gestational and pre-gestational dia-
betes mellitus, previous inappropriate palacentation, 
precelmapsia and patients with chorioamnionitis were 
excluded from our study. No patient in our study had 
taken any hormonal medication during the 6 months 
before gestation. All obtained tissue samples were histo-
pathologically verified using the classical hematoxylin 
and eosin staining techniques after fixation in formalin 
by an experienced pathologist.  Patients agreement was 
obtained in all cases. The approval for the research pro-
gram of the Jagiellonian University Ethical Committee 
was also granted (Table 1).
Table 1: The characteristics of subjects with respect to the maturity of newborns: not fully and fully maturated.
Pregnant women (n=160) Maternal  Gestational  Parity Nulliparous  Newborn  Birth weight  Mean Apgar 
Maturity of newborns age ±SD (y) age ±SD (wk) (%) length±SD(cm) ±SD(g) ±SD
Not fully maturated 6 ≤ K ≤9 (n=31) 29.23(±5.9) 36.19(±2.46) 42 50.4(±2.81) 2729(±586) 8.9(±1.37)
Maturated10 ≤ K ≤12 (n=129) 28.5(±5.07) 38.9(±2.3) 64 52.9(±4.47) 3184(±641) 9.78(±0.6)
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Preparation of tissue extracts and Western blotting
 The placental RCAS1 relative amount and beta-Actin, 
which was chosen as a control protein were assessed by 
Western blot analysis. Relative amount of RCAS1 content 
was estimated in 160 placental tissue samples taken from 
normal vaginal deliveries and from cesareans. The used 
method was described in details in our previous reports 
[47,49,50]. Briefly, following standard tissue preparation 
the RCAS1 antigen was identified as a 32kDa band, beta-
Actin represented a 42 kDa band [8,44,49].
CAP plasma level
The oxytocinase plasma level was established in 160 
plasma samples obtained from pregnant women a few days 
before delivery. The CAP plasma activity was evaluated 
using Tuppy and Nesvadba method, modified by Klimek 
[17]. The assessment of oxytocinase in two pH levels using 
the same substrate (L-cystine-di-β-naphthylamide) results 
in obtaining two peeks of aminopeptidase’s activity (CAP1 
– pH 7.9; and CAP2 – pH 6.7). The detailed method of CAP 
estimation was described in previous studies. The level of 
CAP1 in pH 7.9 was considered in our study [14].
Statistical analysis
The distribution of the data was analyzed using Sha-
piro-Wilk’s test. Relative amounts of CAP, RCAS1 and 
control protein in studied specimens were compared 
with the use of Student‘s t-test for normally distributed 
data and Mann-Whitney U test if non normal distribu-
tion was found. Significance of differences between 
studied groups was set at p<0.05.
Results
Statistically significantly lower newborns’ birth 
weight (p=0.006), length (p=0.0008) and gestational age 
(p=0.00001) were identified in the group of not fully 
matured newborns in comparison to the group of fully 
matured newborns (Table 1).
Analysis of oxytocinase plasma level
Statistically significantly higher oxytocinase plasma 
level was identified in patients from whom newborns 
were classified as fully matured than in patients from 
whom the newborns were classified as not fully matured 
(p=0.005). In both examined groups the analysis of 
oxytocinase plasma activity was performed with respect 
to the presence of the clinical symptoms of spontaneous 
beginning of the labor (Table 2).
No differences in CAP plasma level were observed 
between spontaneous and induced labors within the 
group of not fully matured newborns. Significantly 
higher CAP serum level was observed in case of induced 
labor in comparison to spontaneous within the group of 
matured newborns. 
Analysis of placental RCAS1 level
As the amount of β-Actin placental level in all groups 
was found to be identical (Table 3), this indicates that 
the loading of protein was equal in all samples examined 
and allows to perform a comparative study between 
RCAS1 expression between examined groups.
No differences were noticed in RCAS1 expression 
between matured and not fully matured newborns 
independently of the type of the beginning of the labor. 
Statistically significant differences in RCAS1 placental 
level were identified in two examined groups: not fully 
matured and matured newborns and regarding the type 
of the beginning of the labor: spontaneous or induced 
(respectively p<0.001, p<0.0001) (Table 3).
Within the group of spontaneous delivery no differ-
ences in RCAS1 placental level were observed between 
matured and not fully matured newborns. Similarly no 
differences were noticed in RCAS1 level in the group of 
induced labor between matured and not fully matured 
newborns.
Discussion
The differences in CAP serum level with respect to 
the fetal maturity were identified in our study however 
no RCAS1 expression changes were found regarding 
the fetal maturation. We determined the alterations in 
RCAS1 expression with respect to the occurrence of 
Table 2: Maternal CAP plasma level a few days before the labor with respect to the maturity of newborns: not fully matured and matured.
Variables Maturity Not fully matured Matured
 K-index 6≤ K ≤9(n=31) 10≤ K≤12(n=129)
Average CAP plasma level  Spontaneous labor  6.32(±1.12) 7.22(±2.21)
µmol/l/min (±SD) Induced labor  7.16(±2.11) 9.3(±2.85)
Table 3: Maternal RCAS1 and beta-Actin placental level with respect to the maturity of newborns: not fully maturated and matured.
Variables Maturity Not fully matured Matured
 K-index 6≤ K ≤9(n=31) 10≤ K≤12(n=129)
Relative average of RCAS1  Spontaneous labor  0,8452(±0,2281) 0,5753(±0,3024)
placental amount (±SD) Induced labor  1.536(±0.3677) 0.991(±0.3756)
Relative average of beta-Actin  Spontaneous labor  1.1574(±0.6306) 1.0849(±0.7276)
placental amount (±SD) Induced labor  1.1372(±0.5376) 1.397(±0.4226)
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clinical symptoms of the spontaneous beginning of the 
labor in maturated and not-fully maturated groups of 
newborns. 
Fetal maturity does not seem to be directly con-
nected with the phenomenon of immune tolerance 
during pregnancy although the fetal maturation 
influences the process of initiation of the labor 
at term finishing the immune tolerance during 
pregnancy. The molecular alterations at the mater-
nal-fetal interface lead to the increasing cytotoxic 
immune response and are concomitant to the clinical 
symptoms of spontaneous beginning of the labor and 
seems to be independent of the gestational age. The 
miscarriage, preterm delivery, and the labor at term 
are connected with the growing immune response 
[2,4,9,24,29,33,43]. The relation between NK cells 
infiltration of fetal structures and RCAS1 expression 
drop in trophoblast cells in miscarriage in the third 
trimester of pregnancy compared with  the normal 
pregnancy was described by Ohshima et al [28]. 
The participation of NK cells and the growth of Th1 
depended response in decidua in miscarriage is well 
known [35,39]. NK cells are responsible for the con-
trol of trophoblast invasion and vascular remodeling 
in decidua [3]. Normal ovum implantation is also 
connected with Th1 cytokines secretion, what might 
indicate that the pregnancy growth is not only domi-
nated by Th2 immunity [39]. Though not only Th1/
Th2 balance is responsible for the immune tolerance 
during pregnancy [5]. CD4+CD25high regulatory 
lymphocytes seem to participate also in this process 
[11]. Van Rango et al. demonstrated higher Il-4 con-
centration in decidua parietalis while INF gamma 
accumulation in decidua basalis, what indicates dif-
ferent cytotoxic cells distribution around the ovum 
[46]. Mother recruits NK cells to the decidua during 
the whole pregnancy [34]. Immune tolerance seems 
to be the result of dynamic balance between growing 
cytotoxic response from one side and factors inhibit-
ing the fulfillment of this reaction by the expression 
of factors and their secretion (Fas-L, KIR, IDO, LIF, 
RCAS1, CAP and others) at the maternal-fetal inter-
face from the other side [21,25,28,30,31,42]. The shift 
of the balance to the cytotoxic activity takes place at 
the labor. The changes in the NK and macrophages 
number and activity concomitant to the vaginal 
labor in comparison to the cesarean section were 
demonstrated by Sindram-Trujillo et al. [38]. There 
is also a level of immune tolerance even during intra-
uterine fetal demise and stillbirth which also require 
the inhibition of immune tolerance and the growth 
of cytotoxic activity at the maternal-fetal interface, 
what was confirmed in our previous report when the 
placental RCAS1 level analysis was performed during 
stillbirth [50]. Similarly to the analysis of placental 
RCAS1 expression in preterm delivery higher expres-
sion was shown in cases of efficient tocolysis. This 
might suggest the efficacy of magnesium sulfate 
therapy perhaps deciding about the level of immune 
tolerance at the maternal-fetal interface at the moment 
of its beginning [15]. The growing cytotoxic activity 
at the maternal-fetal interface and the changes in 
the uterine cervix determine the labor at term [54]. 
Both processes are controlled by the immunological 
system and have to take place in the proper sequence; 
when the immune response increases too early in 
decidua basalis placental abruption occurs, when the 
immune response growth occurs too late the retained 
placental tissue is observed. It was also described 
in our previous study, when RCAS1 placental level 
was considered in cases of retained placental tissue 
in comparison to placental abruption. Significantly 
higher RCAS1 expression was identified in cases with 
retained placental tissue [53]. Recently lower RCAS1 
placental expression was observed in cases with the 
presence of spontaneous beginning of the labor at 
term in comparison to induced labor at term [49]. 
These observations were confirmed in the current 
study in matured newborns, additionally similar dif-
ference in RCAS1 placental expression was found in 
cases of not fully maturated newborns.  This might 
indicate that the level of maternal immune response 
– immune response inhibition – does not depend on 
the fetal maturation, whereas the placental RCAS1 
level informs about the intensity of the phenomena 
at the maternal-fetal interface. The analysis of RCAS1 
expression with respect to the uterine cervix ripen-
ing during cesarean section revealed the statistically 
significant drop of placental RCAS1 level in cases of 
cervix dilatation more than 2cm [52].
Significant alterations in CAP plasma level with 
respect to the beginning of the labor was concomitant 
only to the labor of matured newborn. This finding 
is also in compliance with our previous observation 
concerning the differences in CAP plasma level in a 
few days before the labor at term according to the type 
of the beginning of the labor – spontaneous or induced 
[49]. CAP activity is a good marker of normal preg-
nancy development [18,26]. In presented study CAP 
plasma level was raising significantly with the growth 
of the fetus. Because of correlation between CAP serum 
activity and the level of fetal maturity CAP is used for 
the prognosis of the time of delivery [14]. This is why 
no differences were found between the spontaneous or 
induced labor of not fully maturated newborn in CAP 
plasma levels. 
In sum our findings might indicate that the evalua-
tion of CAP plasma level and RCAS1 placental expres-
sion would inform about the processes taking place at 
the maternal-fetal interface. CAP seems to be a useful 
marker of normal fetal development. The assessment 
of RCAS1 in placenta directly after delivery appears to 
indicate the level of maternal immune tolerance during 
the labor initiation. The level of the immune tolerance 
at the moment of the delivery drops independently of 
the fetal maturity. 
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